Clinic
Crossroads Treatment Center of Louisville, PSC
Crossroads Treatment Center of Louisville, PSC was paid $13.68M by Medicaid between Sep 2018 and Dec 2024, across 28 billing codes. Its largest line is H0020, Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) — 60% of everything it billed.
33Billing provider infoCROSSROADS TREATMENT CENTER OF LOUISVILLE, PSC
JEFFERSONTOWN, KY 40299
JEFFERSONTOWN, KY 40299
33aNPI1649797507assigned 08/23/2017
33bProvider typeMulti-Specialty Clinic/Center
28Total paid$13.68M
24GClaims416,490
24DCodes billed28
24AFirst – last monthSep 2018 – Dec 2024
Compared with peers
Next to other Multi-Specialty Clinic/Center providers in Kentucky
Rank by total paid#1 of 27
Median peer was paid$357K
This provider vs. median38×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MCCORMAC, RUPERT controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,973 | $30K | |
| 2019 | 172,276 | $914K | |
| 2020 | 100,539 | $3.30M | |
| 2021 | 39,674 | $2.20M | |
| 2022 | 22,915 | $1.92M | |
| 2023 | 42,510 | $2.73M | |
| 2024incomplete | 35,603 | $2.60M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | 60% | 133,968 | 24,677 | $8.16M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 10% | 14,179 | 7,117 | $1.38M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 9.3% | 178,461 | 7,559 | $1.27M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 5.4% | 16,969 | 9,954 | $738K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 3.3% | 5,298 | 4,883 | $447K |
| T1007 | Alcohol and/or substance abuse services, treatment plan development and/or modification | 2.3% | 5,438 | 4,275 | $320K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.9% | 7,063 | 4,644 | $263K |
| 99408 | 1.8% | 25,361 | 1,102 | $240K | |
| H0033 | Oral medication administration, direct observation | 1.6% | 2,448 | 2,185 | $217K |
| H0016 | Alcohol and/or drug services; medical/somatic (medical intervention in ambulatory setting) | 1.4% | 1,982 | 1,058 | $196K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.1% | 5,716 | 3,668 | $154K |
| 82075 | <1% | 5,061 | 4,471 | $110K |
16 more codes
| 90832 | Psychotherapy session, about 30 minutes | <1% | 6,110 | $82K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 281 | $44K |
| 80305 | <1% | 1,999 | $19K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 247 | $9K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 249 | $8K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 1,079 | $7K |
| 99441 | <1% | 2,339 | $4K | |
| 99406 | <1% | 719 | $4K | |
| 81025 | <1% | 345 | $2K | |
| G2067 | Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a medicare-enrolled opioid treatment program) | <1% | 184 | $2K |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 593 | $1K |
| 36415 | Collection of venous blood by venipuncture | <1% | 99 | $505.24 |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 60 | $468.08 |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 71 | $395.96 |
| 86580 | <1% | 139 | $194.27 | |
| 96127 | <1% | 32 | $34.74 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCCORMAC, RUPERT (CHIEF EXECUTIVE OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.